Summary
Idorsia Ltd, a biopharmaceutical company, discovers, develops, and commercializes drugs for unmet medical needs in Switzerland. The company has a clinical development pipeline that cover various therapeutic areas, including CNS, cardiovascular, and immunological disorders, as well as orphan diseases. Idorsia Ltd has a collaboration agreement with Janssen Biotech Inc. to jointly develop and commercialize aprocitentan and its derivative compounds or products; license agreement with Mochida Pharmaceutical for the supply, co-development, and comarketing of daridorexant; and Hoffman-La Roche Inc. to develop and market compounds in the field of cancer immunotherapy. It also has a collaboration with Antares Pharma, Inc. for the development of a self- administered drug device product for Selatogrel; and Neurocrine Biosciences, Inc. to develop and commercialize ACT-709478, which is in Phase II clinical trial for the treatment of epilepsy. The company was incorporated in 2017 and is headquartered in Allschwil, Switzerland.
History
Idorsia was founded in 2015 by Novartis and Actelion. Idorsia was born out of the strong heritage of its two parent companies, Novartis and Actelion, both of which have businesses in the development of small molecules and biologics. Idorsia leverages the expertise and experience of both companies to continue the journey of developing new products and treatments to address unmet medical needs.
Mission
At Idorsia, we are dedicated to developing novel medicines that address large unmet medical needs. Our mission is to be a global leader in discovering, developing, and commercializing innovative biopharmaceutical products that improve the wellbeing and quality of life of patients with significant unmet medical needs.
Vision
Our vision is to provide meaningful innovations to improve the health of patients around the world. We strive to create value with the development of novel medicines, making sure that this value is transferred from the most advanced scientific research to the patient.
Key Team
Mr. Alexander Khatuntsev (Sr. VP & Head of Global HR)
Mr. Andrew C. Weiss (Sr. VP and Head of Investor Relations & Corp. Communications)
Dr. Guy Braunstein M.D. (Exec. VP & Chief Medical Officer)
Mr. Julien Gander L.L.M. (Sr. VP, Group Gen. Counsel & Company Sec.)
Mr. Simon Jose (Exec. VP & Chief Commercial Officer)
Mr. Olivier Lambert (Sr. VP and Head of Global Pharmaceutical Devel. & Quality Assurance)
Mr. Markus A. Riederer (Sr. VP & Head of Drug Discovery Biology)
Recognition and Awards
The Idorsia team has been recognized for its commitment to drug discovery and development, and has been honored with numerous awards, including the European Society for Medical Oncology Award for Innovation and Excellence , the Swiss Employers’ Award for Innovation , and the European Federation of Pharmaceutical Industries and Associations Prize for Innovation .
References
Switzerland 